Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers The primary objective of the study ...

CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies. Knowledge of the KRAS G12C mutations can be very important for ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

A previous study showed a confirmed objective response rate of 42.9% with the KRAS G12C inhibitor adagrasib in previously treated patients with NSCLC. In this phase III trial, median progression-free ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor sotorasib This biomarker may help physicians determine those most likely to ...

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...

This is read by an automated voice. Please report any issues or inconsistencies here. Los Angeles-based clinical-stage biopharmaceutical company Trethera Corp. received a $2.7-million Small Business ...